⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18235878 | 0.88 | — | — | |
| Iodide SCHEMBL31464003 | 0.85 | — | — | |
| SCHEMBL7172409 | 0.81 | — | — | |
| SCHEMBL12321647 | 0.78 | — | — | |
| SCHEMBL11664768 | 0.78 | — | — | |
| SCHEMBL197462 | 0.78 | — | — | |
| SCHEMBL13168333 | 0.78 | — | — | |
| SCHEMBL8438410 | 0.78 | — | — | |
| SCHEMBL2416224 | 0.78 | — | — | |
| Ammonia Solution, Strong SCHEMBL197463 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1865962-A2 | USE OF N-DESMETHYLCLOZAPINE AND RELATED COMPOUNDS AS DOPAMINE STABILIZING AGENTS | Arcadia Pharmaceuticals Inc. (US) | 2007-12-19 | — | — | EP | claimed |
| WO-2006107948-A2 | USE OF N-DESMETHYLCLOZAPINE AND RELATED COMPOUNDS AS DOPAMINE STABILIZING AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2006-10-12 | — | — | WO | claimed |
| US-20020099054-A1 | 2-phenyl benzimidazole derivatives as MCP-1 antagonists | WARNER-LAMBERT COMPANY (US) | 2002-07-25 | — | — | US | claimed |
| US-6184235-B1 | MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1) ANTAGONIST FOR TREATMENT OF INFLAMMATORY DISEASES, ATHEROSCLEROSIS, RESTENOSIS, AUTOIMMUNE DISEASES, ORGAN TRANSPLANT REJECTION IN MAMMALS | WARNER-LAMBERT COMPANY | 2001-02-06 | — | — | US | claimed |
| CN-119698406-A | Nanomaterials comprising triols | 比姆医疗股份有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-118908962-A | Heterobifunctional compounds as degradation agents for HPK1 | 西奈山伊坎医学院 | 2024-11-08 | — | — | CN | disclosed |
| CN-118900689-A | Oxazolidinone liposome compositions | 阿卡格拉医药公司 | 2024-11-05 | — | — | CN | disclosed |
| CN-118324761-A | USP inhibitor, preparation method and application thereof | 北京华森英诺生物科技有限公司 | 2024-07-12 | — | — | CN | disclosed |
| EP-4380920-A1 | INHIBITORS FOR CORONAVIRUSES | Cocrystal Pharma, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| CN-118063438-A | MDM2/MDMX double-target inhibitor compound, prodrug, pharmaceutical composition, preparation method and application thereof | 北京华益健康药物研究中心 | 2024-05-24 | — | — | CN | disclosed |
| WO-2023014758-A1 | INHIBITORS FOR CORONAVIRUSES | COCRYSTAL PHARMA, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| CN-114835586-B | Efficient preparation method for N, N-diethyl ethylenediamine | 泽升科技(广州)有限公司 | 2022-09-13 | — | — | CN | disclosed |
| US-6534521-B2 | Useful in the treatment of inflammation, atherosclerosis, restenosis, and immune disorders such as arthritis and transplant rejection | MILLENNIUM PHARMACEUTICALS, INC. | 2003-03-18 | — | — | US | disclosed |
| US-20020099054-A1 | 2-phenyl benzimidazole derivatives as MCP-1 antagonists | WARNER-LAMBERT COMPANY (US) | 2002-07-25 | — | — | US | disclosed |
| US-6348487-B1 | ANTIINFLAMMATORY AGENTS, ATHEROSCLEROSIS, RESTINOSIS AND IMMUNE DISORDERS | MILLENNIUM PHARMACEUTICALS, INC. | 2002-02-19 | — | — | US | disclosed |
| US-6184235-B1 | MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1) ANTAGONIST FOR TREATMENT OF INFLAMMATORY DISEASES, ATHEROSCLEROSIS, RESTENOSIS, AUTOIMMUNE DISEASES, ORGAN TRANSPLANT REJECTION IN MAMMALS | WARNER-LAMBERT COMPANY | 2001-02-06 | — | — | US | disclosed |
| EP-0927167-A1 | 2-PHENYL BENZIMIDAZOLE DERIVATIVES AS MCP-1 ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-07-07 | — | — | EP | disclosed |
| WO-1998006703-A1 | 2-PHENYL BENZIMIDAZOLE DERIVATIVES AS MCP-1 ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-02-19 | — | — | WO | disclosed |
| EP-0290377-B1 | Substituted 4-[1H-Imidazol-1-yl] benzamides as antiarrhythmic agents | SCHERING AG (DE) | 1994-03-02 | — | — | EP | disclosed |
| EP-0290377-A1 | Substituted 4-[1H-Imidazol-1-yl] benzamides as antiarrhythmic agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-11-09 | — | — | EP | disclosed |